A phase I trial of the oral cyclin dependent kinase inhibitor CYC202 in patients with advanced malignancy.


3042 Background: CYC202 is an oral cyclin dependent kinase inhibitor of CDKs-2, -7 and -9, leading to inhibition of phosphorylation of CDK substrates, cell cycle arrest, inhibition of transcription and induction of apoptotsis. Preclinical studies show activity in cell lines and xenografts. This trial determines the safety and pharmacokinetics (PK) of CYC202… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.